Bhujbal Santosh, Rupenthal Ilva D, Steven Philipp, Agarwal Priyanka
Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, Aotearoa-New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Clinic I for Internal Medicine and Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
J Ocul Pharmacol Ther. 2024 Dec;40(10):638-658. doi: 10.1089/jop.2024.0103. Epub 2024 Oct 2.
Dry eye disease (DED) is a rapidly growing ocular surface disease with a significant socioeconomic impact that affects the patients' visual function and, thus, their quality of life. It is distinguished by a loss of tear film homeostasis, leading to tear film instability, hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities, with all of these playing etiological roles in the propagation of the vicious DED circle. While current treatments primarily focus on reducing tear film instability and hyperosmolarity, increasingly more attention is being placed on tackling the underlying inflammation that propagates and potentiates these factors. As such, preclinical models are crucial to further elucidate the DED pathophysiology and develop novel therapeutic strategies. This review outlines the role of inflammation in DED, highlighting related signs and diagnostic tools before focusing on relevant preclinical animal models and potential therapeutic strategies to tackle DED-associated inflammation.
干眼症(DED)是一种迅速发展的眼表疾病,具有重大的社会经济影响,会影响患者的视觉功能,进而影响其生活质量。它的特点是泪膜稳态丧失,导致泪膜不稳定、高渗、眼表炎症和神经感觉异常,所有这些因素在干眼症恶性循环的发展中都起着病因学作用。虽然目前的治疗主要集中在减少泪膜不稳定和高渗,但越来越多的注意力正放在解决引发和加剧这些因素的潜在炎症上。因此,临床前模型对于进一步阐明干眼症的病理生理学和开发新的治疗策略至关重要。本综述概述了炎症在干眼症中的作用,重点介绍了相关体征和诊断工具,然后着重探讨了相关的临床前动物模型以及应对干眼症相关炎症的潜在治疗策略。